Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Dr Sen says the biggest challenge to lurbinectedin maintenance is Delphi 305, which tests terlatumab plus durvalumab against durvalumab alone after induction chemoimmunotherapy. Its phase 3 results could reshape first-line maintenance before the durvalumab-lurbinectedin question matters, so it is the single key readout to watch.

Related Insights

Unlike traditional cytotoxic agents, the DLL3-targeting T-cell engager tarlatumab demonstrates consistent overall survival benefits in third-line SCLC regardless of the patient's chemotherapy-free interval from first-line therapy. This indicates it works via a distinct mechanism that bypasses conventional chemoresistance pathways, representing a new treatment paradigm.

Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.

While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."

While the Keynote 585 trial (doublet chemo + pembrolizumab) failed overall, its small FLOT chemotherapy subgroup mirrored the positive results of the Matterhorn trial (FLOT + durvalumab). This suggests the choice of a less aggressive chemotherapy backbone, not the immunotherapy concept, was the critical factor in the trial's negative outcome.

The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.

Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.

If the Delphi-305 trial for the T-cell engager Tarlatumab is positive in the first-line maintenance setting for small cell lung cancer, it would likely eliminate any clinical role for Lurbinectedin, another therapy currently used in that space. This highlights how a single trial outcome can dramatically reshape treatment standards and render existing options obsolete.

An expert emphasizes the historic importance of the Delphi 304 trial, noting it is the only randomized study in second-line SCLC to ever demonstrate a clear survival benefit against an active chemotherapy control arm. The drug showed superiority across all major endpoints, setting a definitive new standard of care.

Early data for Tarlatamab in SCLC maintenance reveals an 82% 12-month overall survival. This is an absolute 30% improvement over the experimental arm of the recent MFORTE trial, signaling a potential paradigm shift in treatment outcomes that far surpasses current immunotherapy combinations.

Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.